Post-COVID-19 invasive fungal infections in pulmonary ICU patients: Diagnosis, management, and clinical challenge
DOI:
https://doi.org/10.61882/jcbior.6.3.330Keywords:
Invasive fungal infection, Aspergillosis, Candidiasis, Mucorales, Critical careAbstract
Invasive fungal infections (IFIs) are among the most significant and challenging complications in critically ill patients, particularly those with underlying pulmonary diseases. Common causative organisms include Aspergillus, Candida, and Mucorales, which are associated with high morbidity and mortality due to delayed diagnosis, nonspecific clinical presentation, and host immune suppression. This narrative review provides a comprehensive overview of the epidemiology, pathophysiology, diagnostic methods, therapeutic options, and clinical challenges of pulmonary IFIs in intensive care unit (ICU) patients. Risk factors, advances and limitations in imaging, laboratory diagnostics including cultures, biomarkers, and molecular techniques, as well as antifungal treatment strategies are discussed. The review also addresses emerging issues such as antifungal resistance, adjunctive therapies, and the critical role of early recognition in improving clinical outcomes. The aim is to guide ICU clinicians in the effective management of critically ill pulmonary patients with invasive fungal infections while highlighting future research directions.
References
1. Bassetti M, Giacobbe DR, Agvald-Ohman C, Akova M, Alastruey-Izquierdo A, Arikan-Akdagli S, et al. Invasive fungal diseases in adult patients in intensive care unit (FUNDICU): 2024 consensus definitions from ESGCIP, EFISG, ESICM, ECMM, MSGERC, ISAC, and ISHAM. Intensive Care Medicine. 2024;50(4):502–515. DOI: 10.1007/s00134-024-07341-7
2. Jin W, Yang D, Xu Z, Song J, Jin H, Zhou X, et al. Predicting the risk of invasive fungal infections in ICU sepsis population: the AMI risk assessment tool. Infection. 2025;53(4):1425-1435.
DOI: 10.1007/s15010-024-02465-w PMID: 39899210
3. Hlophe ST, Govender NP, Masekela R. Invasive fungal infections among critically ill children: Epidemiology, risk factors and outcomes. Afr J Thorac Crit Care Med. 2018;24(1):10.7196/AJTCCM.2018.v24i1.172.
DOI: 10.7196/AJTCCM.2018.v24i1.172 PMID: 34541495
4. Fang W, Wu J, Cheng M, Zhu X, Du M, Chen C, et al. Diagnosis of invasive fungal infections: challenges and recent developments. J Biomed Sci. 2023;30(1):42.
DOI: 10.1186/s12929-023-00926-2 PMID: 37337179
5. Zaragoza R, Pemán J. Invasive fungal infections in critically ill patients: different therapeutic options and a uniform strategy. Rev Iberoam Micol. 2006;23(2):59-63. DOI: 10.1016/s1130-1406(06)70014-6 PMID: 16854178
6. Wang Y, Yao Y, Zhang Q, Chen H, He Y, Hu K. Clinical courses and outcomes of COVID-19-associated pulmonary aspergillosis in 168 patients with the SARS-CoV-2 Omicron variant. BMC Infectious Diseases. 2024;24:117.
DOI: 10.1186/s12879-023-08971-w
7. Gu Y, Ye X, Liu Y, Wang Y, Shen K, Zhong J, et al. A risk-predictive model for invasive pulmonary aspergillosis in patients with acute exacerbation of chronic obstructive pulmonary disease. Respiratory Research. 2021;22(1):176.
DOI: 10.1186/s12931-021-01771-3
8. Garnacho-Montero J, Barrero-García I, León-Moya C. Fungal infections in immunocompromised critically ill patients. J Intensive Med. 2024;4(3):299-306.
DOI: 10.1016/j.jointm.2024.01.005 PMID: 39035612
9. Trelles M, Murillo J, Fuenmayor-González L, Yu-Liu Y, Alexander-León H, Acebo J, et al. Prevalence of invasive fungal infection in critically Ill patients: a systematic review and meta-analysis. BMC Infect Dis. 2025;25(1):896.
DOI: 10.1186/s12879-025-11264-z PMID: 40615938
10. Danion F, Coste A, Le Hyaric C, Melenotte C, Lamoth F, Calandra T, et al. What Is New in Pulmonary Mucormycosis? Journal of Fungi. 2023;9(3):307. DOI: 10.3390/jof9030307
11. Pham D, Howard-Jones AR, Sparks R, Stefani M, Sivalingam V, Halliday CL, et al. Epidemiology, Modern Diagnostics, and the Management of Mucorales Infections. Journal of Fungi. 2023;9(6):659. DOI: 10.3390/jof9060659
12. Lass-Flörl C, Steixner S. The changing epidemiology of fungal infections. Mol Aspects Med. 2023;94:101215.
DOI: 10.1016/j.mam.2023.101215 PMID: 37804792
13. Xia Y, Jiang W, Zhu X, Pan B, Chen T, Wang Y, et al. Global, Regional, and National Burden of Pulmonary Fungal Infections 1990-2021. Am J Respir Crit Care Med. 2025;211(6):1007-1017. DOI: 10.1164/rccm.202410-2076OC PMID: 40173277
14. Bay P, Audureau E, Fourati S, de Prost, N, COVID-19 associated pulmonary aspergillosis in critically-ill patients – authors’ reply. Ann Intensive Care. 2024;14:112. DOI: 10.1186/s13613-024-01320-3
15. Hall Zimmerman L, Dolman H, Faris J, Park L, Mynatt R, Zimmerman WB, et al. Candidemia Surveillance and Impact on Non-neutropenic Critically Ill Patients. Cureus. 2024;16(11):e73155.
DOI: 10.7759/cureus.73155 PMID: 39650902
16. Salmanton-García J, Cornely OA, Stemler J, Barać A, Steinmann J, Siváková A, et al. Attributable mortality of candidemia - Results from the ECMM Candida III multinational European Observational Cohort Study. J Infect. 2024;89(3):106229.
DOI: 10.1016/j.jinf.2024.106229 PMID: 39025408
17. Brown GD, Denning DW, Levitz SM. Tackling human fungal infections. Science. 2012;336(6082):647.
DOI: 10.1126/science.1222236 PMID: 22582229
18. Ledoux MP, Herbrecht R. Invasive Pulmonary Aspergillosis. J Fungi (Basel). 2023;9(2):131. DOI: 10.3390/jof9020131
PMID: 36836246
19. Alqarihi A, Kontoyiannis DP, Ibrahim AS. Mucorales-initiated epithelial invasion via host cell GRP78 and integrin α3β1 engagement: Role of EGFR in fungal endocytosis. Frontiers in Cellular and Infection Microbiology. 2023;13:1254919.
DOI: 10.3389/fcimb.2023.1254919
20. Rajendran R, Sherry L, Nile CJ, Sherriff A, Johnson EM, Hanson MF, et al. Biofilm formation is a risk factor for mortality in patients with Candida albicans bloodstream infection-Scotland, 2012-2013. Clin Microbiol Infect. 2016;22(1):87-93.
DOI: 10.1016/j.cmi.2015.09.018 PMID: 26432192
21. Salazar F, Bignell E, Brown GD, Cook PC, Warris A. Pathogenesis of Respiratory Viral and Fungal Coinfections. Clin Microbiol Rev. 2022;35(1):e0009421.
DOI: 10.1128/CMR.00094-21 PMID: 34788127
22. Mata-Martínez P, Bergón-Gutiérrez M, Del Fresno C. Dectin-1 signaling update: New perspectives for trained immunity. Frontiers in Immunology. 2022;13:812148. DOI: 10.3389/fimmu.2022.812148
23. Thammasit P, Sripetchwandee J, Nosanchuk JD, Chattipakorn SC, Chattipakorn N, Youngchim S. Cytokine and Chemokine Responses in Invasive Aspergillosis Following Hematopoietic Stem Cell Transplantation: Past Evidence for Future Therapy of Aspergillosis. J Fungi (Basel). 2021;7(9):753.
DOI: 10.3390/jof7090753 PMID: 34575791
24. Lionakis MS, Drummond RA, Hohl TM. Immune responses to human fungal pathogens and therapeutic prospects. Nat Rev Immunol. 2023;23(7):433-452. DOI: 10.1038/s41577-022-00826-w PMID: 36600071
25. Crossen AJ, Ward RA, Reedy JL, Surve MV, Klein BS, Rajagopal J, et al. Human Airway Epithelium Responses to Invasive Fungal Infections: A Critical Partner in Innate Immunity. Journal of Fungi. 2023;9(1):40. DOI: 10.3390/jof9010040
26. Lee JS, Kim C. Role of CARD9 in Cell- and Organ-Specific Immune Responses in Various Infections. International Journal of Molecular Sciences. 2024;25(5):2598.
DOI: 10.3390/ijms25052598
27. Günther K, Nischang V, Cseresnyés Z, Krüger T, Sheta D, Abboud Z, et al. Aspergillus fumigatus-derived gliotoxin impacts innate immune cell activation through modulating lipid mediator production in macrophages. Immunology. 2024;173(4):748-767. DOI: 10.1111/imm.13857 PMID: 39268960
28. Atiencia-Carrera MB, Cabezas-Mera FS, Vizuete K, Debut A, Tejera E, Machado A. Evaluation of the biofilm life cycle between Candida albicans and Candida tropicalis. Front Cell Infect Microbiol. 2022;12:953168.
DOI: 10.3389/fcimb.2022.953168 PMID: 36061861
29. Amann V, Kissmann A-K, Firacative C, Rosenau F. Biofilm-Associated Candidiasis: Pathogenesis, Prevalence, Challenges and Therapeutic Options. Pharmaceuticals. 2025;18(4):460.
DOI: 10.3390/ph18040460
30. Palmieri F, Koutsokera A, Bernasconi E, Junier P, von Garnier C, Ubags N. Recent Advances in Fungal Infections: From Lung Ecology to Therapeutic Strategies With a Focus on Aspergillus spp. Front Med (Lausanne). 2022;9:832510.
DOI: 10.3389/fmed.2022.832510 PMID: 35386908
31. Koehler P, Bassetti M, Chakrabarti A, Chen SCA, Colombo AL, Hoenigl M, et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. The Lancet Infectious Diseases. 2021;21(6):e149-e162. DOI: 10.1016/S1473-3099(20)30847-1 PMID: 33333012
32. Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;24 Suppl 1:e1-e38.
DOI: 10.1016/j.cmi.2018.01.002 PMID: 29544767
33. Perfect JR. Cryptococcosis: a model for the understanding of infectious diseases. J Clin Invest. 2014;124(5):1893-5.
DOI: 10.1172/JCI75241 PMID: 24743152
34. Hoenigl M, Seidel D, Sprute R, Cunha C, Oliverio M, Goldman GH, et al. COVID-19-associated fungal infections. Nat Microbiol. 2022;7(8):1127-1140. DOI: 10.1038/s41564-022-01172-2 PMID: 35918423
35. Prattes J, Wauters J, Giacobbe DR, Salmanton-García J, Maertens J, Bourgeois M, et al. Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients-a multinational observational study by the European Confederation of Medical Mycology. Clin Microbiol Infect. 2022;28(4):580-587. DOI: 10.1016/j.cmi.2021.08.014 PMID: 34454093
36. Verweij PE, Gangneux JP, Bassetti M, Brüggemann RJ, Cornely OA, Koehler P, et al. Diagnosing COVID-19-associated pulmonary aspergillosis. Correction to Lancet Microbe 2020; published online May 8. The Lancet Microbe. 2020;1(3):e108.
DOI: 10.1016/S2666-5247(20)30027-6
37. Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis. Nat Rev Dis Primers. 2018;4:18026. DOI: 10.1038/nrdp.2018.26 PMID: 29749387
38. Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19(12):e405-e421. DOI: 10.1016/S1473-3099(19)30312-3 PMID: 31699664
39. Johannson KA, Huston SM, Mody CH, Davidson W. Cryptococcus gattii pneumonia. CMAJ. 2012;184(12):1387-90. DOI: 10.1503/cmaj.111346 PMID: 22891210
40. Lewis RE, Stanzani M, Morana G, Sassi C. Radiology-based diagnosis of fungal pulmonary infections in high-risk hematology patients: are we making progress? Curr Opin Infect Dis. 2023;36(4):250-256. DOI: 10.1097/QCO.0000000000000937 PMID: 37431554
41. Alamo L, Ceppi F, Tenisch E, Beigelman-Aubry C. CT imaging findings of invasive pulmonary fungal infections in hemato-oncologic children. Insights Imaging. 2024;15:296. DOI: 10.1186/s13244-024-01871-w
42. Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1-e60. DOI: 10.1093/cid/ciw326 PMID: 27365388
43. Sami CA, Rashed HM, Khan AH, Barai L, Arafat SM. Disseminated mucormycosis: An unusual case of ascites with bone marrow invasion. IDCases. 2022;29:e01553.
DOI: 10.1016/j.idcr.2022.e01553 PMID: 35845829
44. White PL, Bretagne S, Caliendo AM, Loeffler J, Patterson TF, Slavin M, et al. Aspergillus Polymerase Chain Reaction-An Update on Technical Recommendations, Clinical Applications, and Justification for Inclusion in the Second Revision of the EORTC/MSGERC Definitions of Invasive Fungal Disease. Clin Infect Dis. 2021;72 Suppl 2:S95-S101.
DOI: 10.1093/cid/ciaa1865 PMID: 33709129
45. Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clinical Infectious Diseases. 2020;71(6):1367–1376.
DOI: 10.1093/cid/ciz1008
46. Arendrup MC, Friberg N, Mares M, Kahlmeter G, Meletiadis J, Guinea J. How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST). Clin Microbiol Infect. 2020;26(11):1464-1472.
DOI: 10.1016/j.cmi.2020.06.007 PMID: 32562861
47. Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother. 2014;69(5):1162-76.
DOI: 10.1093/jac/dkt508 PMID: 24379304
48. White SK, Schmidt RL, Walker BS, Hanson KE. (1→3)-β-D-glucan testing for the detection of invasive fungal infections in immunocompromised or critically ill people. Cochrane Database Syst Rev. 2020;7(7):CD009833.
DOI: 10.1002/14651858.CD009833.pub2 PMID: 32693433
49. Azoulay E. On the tightrope between life and graft: immunosuppression in critically ill solid organ transplant recipients. Intensive Care Med. 2025;51(9):1699-1702.
DOI: 10.1007/s00134-025-08061-2 PMID: 40828462
50. Singh SJ, Fonseca AJ, Rajyaguru S. Evaluation of adherence with lung-protective ventilator strategies in moderate-to-severe acute respiratory distress syndrome in a tertiary care setup in India: A prospective observational study. Int J Crit Illn Inj Sci. 2023;13(2):60-65. DOI: 10.4103/ijciis.ijciis_66_22
PMID: 37547188
51. Mills SEA, Yeldandi AV, Odell DD. Surgical Treatment of Multifocal Pulmonary Mucormycosis. Ann Thorac Surg. 2018;106(2):e93-e95. DOI: 10.1016/j.athoracsur.2017.12.033 PMID: 29391149
52. Zhu C, Gu Y, Zhu Q, Liu X, Jiang T. Management of Invasive Bronchopulmonary Mucormycosis with Low-Dose Antifungal Therapy and Left Lower Lobectomy in a Patient with Renal Insufficiency. Infect Drug Resist. 2025;18:3629-3635.
DOI: 10.2147/IDR.S529536 PMID: 40727386
53. Mahalaxmi I, Jayaramayya K, Venkatesan D, Subramaniam MD, Renu K, Vijayakumar P, et al. Mucormycosis: An opportunistic pathogen during COVID-19. Environ Res. 2021;201:111643. DOI: 10.1016/j.envres.2021.111643
54. Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab Syndr. 2021;15(4):102146.
DOI: 10.1016/j.dsx.2021.05.019 PMID: 34192610
55. Lukka VK, Kumar Chowdary K, Bandaru SL, Naga Saritha K. COVID-19-Associated Mucormycosis: Outcomes From a Tertiary Care COVID-19 Hospital. Cureus. 2025;17(7):e87104. DOI: 10.7759/cureus.87104 PMID: 40747169
56. Madhavan Y, Sai KV, Shanmugam DK, Manimaran A, Guruviah K, Mohanta YK, et al. Current Treatment Options for COVID-19 Associated Mucormycosis: Present Status and Future Perspectives. J Clin Med. 2022;11(13):3620.
DOI: 10.3390/jcm11133620
57. Mayr A, Lass-Flörl C. Epidemiology and antifungal resistance in invasive Aspergillosis according to primary disease: review of the literature. Eur J Med Res. 2011;16(4):153-7. DOI: 10.1186/2047-783x-16-4-153 PMID: 21486729
58. Kamath S, Hammad Altaq H, Abdo T. Management of Sepsis and Septic Shock: What Have We Learned in the Last Two Decades? Microorganisms. 2023;11(9):2231.
DOI: 10.3390/microorganisms11092231 PMID: 37764075
59. Azim A, Ahmed A. Diagnosis and management of invasive fungal diseases in non-neutropenic ICU patients, with focus on candidiasis and aspergillosis: a comprehensive review. Front Cell Infect Microbiol. 2024;14:1256158.
DOI: 10.3389/fcimb.2024.1256158 PMID: 38505289
60. Farrokhpour M, et al. Concurrent EGFR and KRAS mutations in non-small cell lung cancer: Challenging the paradigm of linear targeted therapy. Journal of Current Biomedical Reports. 2025;6(2). DOI: 10.61882/jcbior.6.2.299
61. Bussini L, Bartoletti M, Bassetti M, Cortegiani A, De Pascale G, De Rosa FG, et al. Role of liposomal amphotericin B in intensive care unit: an expert opinion paper. J Anesth Analg Crit Care. 2025;5:23. DOI: 10.1186/s44158-025-00236-z
62. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-50. DOI: 10.1093/cid/civ933 PMID: 26679628
Downloads
Published
Issue
Section
License
Copyright (c) 2025 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
